<DOC>
	<DOCNO>NCT02535286</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness pembrolizumab combination ublituximab TGR-1202 , patient advance CLL .</brief_summary>
	<brief_title>Study Pembrolizumab Combination With Ublituximab TGR-1202 Patients With Relapsed-refractory CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Confirmed diagnosis Bcell Chronic Lymphocytic Leukemia Refractory relapse least 1 prior treatment regimen Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Known hepatitis B virus , hepatitis C virus HIV infection Known histological transformation CLL aggressive lymphoma prolymphocytic leukemia Active autoimmune disorder ( exception autoimmune hemolytic anemia ITP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>